Excellent presentation from Anna Maria Peri on the utility of culture-independent RDTs in BSIs. ADVANCE-ID Network

American Thoracic Society/Centers for Disease Control and Prevention/European Respiratory Society/Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) Updated guideline on the treatment of tuberculosis ✅ Just Accepted 🔗 bit.ly/3XAxXLp

It was great to be the first speaker at the 15th Febrile Neutropenia Symposium this year. I am delighted to hear that ECIL-10 guidelines for emp/targeted abx therapy of febrile neutropenia will come out soon The Lancet Infectious Diseases Scientific programme👇🏻ICHS-Global ESCMID

Want to know if temocillin is non-inferior to meropenem in BSI by 3GCeph resistant enterobacteria? We are presenting the results of ASTARTÉ trial at ESCMID Global Sunday 16:15 Hall 9. Francesco Cogliati Dezza Hospital Virgen Macarena IBiS FISEVI Facultad de Medicina de Sevilla Instituto de Salud Carlos III (ISCIII)

Happening soon at #ESCMIDGlobal 2025! Don’t miss David Paterson’s powerful keynote lecture on "Asia: an AMR hot zone." Discover the impact of AMR in Asia, insights from the ACORN-HAI study, and key strategies to fight drug-resistant infections.

🎙️ Join this upcoming webinar on 22 May 2025, which will showcase the importance of clinical trials after licensing antibiotics by demonstrating two major trials taking place. Register now: lnkd.in/gsqVQCKZ

So excited that ADVANCE-ID Network has commenced recruitment into our world first platform trial for carbapenem-resistant Gram negatives! Patrick Harris Jesus Rodriguez Baño

🗓️On Thursday, July 10, Antibacterial Resistance Leadership Group member David Paterson will share his expertise in a webinar on designing adaptive clinical trials.

👏And that's a wrap on CRE RESPOND's Population Pharmacokinetics Workshop 2025!👏 These past 3 days have been a huge success thanks to Patty Mitre who has guided us through the complexities of population pharmacokinetic modelling, from fundamentals to clinical practice💊 We

We are pleased to announce that earlier this month, we enrolled the first patient into the CRGNB silo of the TREAT-GNB platform trial! TREAT-GNB was also recently initiated at another two hospital centres in China. Read more: ad-id.co/t1

Less is more!! Can you believe that?! I had to read the statement many times! Antibiotic therapy non-significantly increased acute pyelonephritis risk by 19% (RR :1.19, 95% CI 0.72-1.94; I2=0%) and symptomatic UTI risk by 18% (RR 1.18, 95% CI 0.78-1.78; I2=28%) vs. no therapy.

This was something I was trained to do in renal transplant clinic as a resident 4 small RCTs combined do not convincingly demonstrate dramatic benefit for this practice But confidence intervals so wide cannot also exclude meaningful harm or benefit

Current evidence does not support routine screening and treatment of post-transplant ASB in KTRs #idxposts

Very likely asymptomatic bacteriuria is far overtreated esp in kidney transplant recipients, however would be good to see further data acutely post transplant and if any signs/symptoms of infection

Effectiveness and safety of antibiotics in kidney transplant recipients with asymptomatic bacteriuria: a systematic review and meta-analysis of randomised controlled trials ✅ Just Accepted 🔗 bit.ly/3JKiLqC

Effectiveness and safety of antibiotics in kidney transplant recipients with asymptomatic bacteriuria: a systematic review and meta-analysis of randomised controlled trials ✅ Just Accepted 🔗 bit.ly/4lSOvYd

Asymptomatic bacteriuria (ASB) is generally systematically screened and treated with antibiotics in kidney transplant recipients (KTRs). In Open Forum Infectious Diseases, authors explore the role of antibiotic therapy in management of ASB in KTRs. academic.oup.com/ofid/advance-a…

Great to here at #GAMRIC2025 in London with David Paterson kicking off all things #AMR

Snapshot genomic surveillance reveals insights into antimicrobial resistance and lineage diversity of uropathogens in older adults in Queensland Brian Forde UQ News Budi Permana academic.oup.com/ofid/article/d…

Cefiderocol is noninferior to standard of care empiric treatment of noscomial Gram-negative bloodstream infections in open-label "Game-Changer" trial. #IDtwitter #medtwitter contagionlive.com/view/cefideroc…